Skip to main content
NCBI home page
Neural Regeneration Research logoLink to Neural Regeneration Research
. 2018 Nov;13(11):1981–1987. doi: 10.4103/1673-5374.239446

Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine

Su Peng 1,#, Li Xu 1,#, Jin-Yu Ma 1, Xiao-Song Gu 1, Cheng Sun 1,*
PMCID: PMC6183036  PMID: 30233073

graphic file with name NRR-13-1981-g001.jpg

Keywords: nerve regeneration, Achyranthes bidentata polypeptides, neuroprotection, cell apoptosis, neurotoxin, mitochondrial dysfunction, cell viability, Bcl-2/Bax, neural regeneration

Abstract

It has been well documented that Achyranthes bidentata polypeptides (ABPPs) are potent neuroprotective agents in several types of neurons. However, whether ABPPs protect dopaminergic neurons from apoptosis induced by neurotoxins is still unknown. This study was designed to observe the effect of ABPPk, a purified fraction of ABPPs, on apoptosis of dopaminergic neurons. SH-5YHY cells and primary dopaminergic neurons were pre-treated with ABPPk (25, 50, or 100 ng/mL) for 12 hours. Cells were then exposed to 6-hydroxydopamine (50 or 150 μM) or rotenone (50 or 200 μM) for 36 hours to induce cell apoptosis. Our results demonstrate that ABPPk markedly increased viability in SH-SY5Y cells and primary dopaminergic neurons, decreased lactate dehydrogenase activity and number of apoptotic dopaminergic neurons, elevated mitochondrial membrane potential, and increased Bcl-2/Bax ratio. These findings suggest that ABPPk protects dopaminergic neurons from apoptosis, and that ABPPk treatment might be an effective intervention for treating dopaminergic neuronal loss associated with disorders such as Parkinson's disease.

Introduction

Traditional Chinese Medicine is a treasure trove for discovering novel drugs against various disorders, with artemisinin being an outstanding example in this field (Kong and Tan, 2015). It has been well documented that Achyranthes bidentata plays beneficial roles against various human disorders. Several bioactive substances including polysaccharide, ginsenoside, and saponin have been isolated from Achyranthes bidentata, and their biological functions extensively studied (Shen et al., 2010; Zou et al., 2011; He et al., 2014; Jiang et al., 2017). Except for polysaccharide and saponin, Achyranthes bidentata polypeptides (ABPPs) are also bioactive constituents. Therefore, we have focused our interest on ABPPs for more than 10 years. Several studies have found that ABPPs protect hippocampal neurons from N-methyl-D-aspartic acid-induced cell apoptosis (Shen et al., 2008, 2010). While we have previously shown that ABPPs protect neurons from serum and/or glucose deprivation in vitro and in vivo (Shen et al., 2011, 2013; Yu et al., 2014). Besides the central nervous system, ABPPs also play an important role in promoting sciatic nerve regrowth after injury (Yuan et al., 2010; Wang et al., 2013; Cheng et al., 2014). Recently, we identified one fraction, named ABPPk, which exhibits the greatest neuroprotective efficiency for promoting peripheral nerve regeneration after crush injury (Yu et al., 2014). Since ABPPs are neuroprotective, it is reasonable to predict that ABPPk may have beneficial roles in treating neuronal loss associated with disorders such as Parkinson's disease (PD).

To test this hypothesis in this study, we pre-treated dopaminergic neurons with ABPPk and then subjected the cells to exogenous insults induced by neurotoxic agents including rotenone and 6-hydroxydopamine (6-OHDA). Our objective was to determine whether ABPPk protects dopaminergic neurons from apoptosis induced by neurotoxins.

Materials and Methods

ABPPk isolation and purification

Achyranthes bidentata blume roots were purchased from a local Chinese medicine store, and identified by Professor Haoru Zhao from China Pharmaceutical University (Nanjing, China). The crude ABPP extraction procedure has been previously described (Shen et al., 2008). ABPPk fraction was purified by high performance liquid chromatography (Cheng et al., 2014; Yu et al., 2014).

Cell culture and treatment

Human dopaminergic SH-SY5Y cells were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA), and cultured in Dulbecco's modified Eagle's medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco), and incubated in a humidified atmosphere with 5% CO2 at 37°C. Primary rat midbrain dopaminergic neurons were prepared from newborn Sprague-Dawley rat (P0) brains, as described elsewhere (Gandhi et al., 2009). SH-SY5Y cells and primary midbrain dopaminergic neurons were treated with 6-OHDA (50 or 150 μM; Sigma-Aldrich, St. Louis, MO, USA) or rotenone (50 or 200 μM; Sigma-Aldrich) for 36 hours with or without 12 hour-pretreatment of ABPPk (25, 50, or 100 ng/mL).

Cell viability assay

Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Cells were seeded into 96-well plates and treated with 6-OHDA (50 or 150 μM) or rotenone (50 or 200 μM) for 36 hours with 12 hour-pretreatment of ABPPk (25, 50, or 100 ng/mL). Subsequently, the medium was removed. MTT (final concentration 500 μg/mL; Sigma-Aldrich) was added and incubated at 37°C for 4 hours. After incubation, cells were lysed in sodium dodecyl sulphate (20%) at 37°C for 20 hours. Absorbance at 570 nm was measured using a microplate reader (BioTek, Winooski, VT, USA).

Terminal deoxynucleotidyltransferase-mediated-uridine triphosphate nick-end labeling (TUNEL) staining of apoptotic cells

TUNEL analysis was performed using a kit (Roche, Penzberg, Germany). Briefly, after fixation for 1 hour in 4% paraformaldehyde at room temperature, cells were permeabilized for 2 minutes on ice. After thoroughly washing, 1500 U/mL DNase 1 (100 μL) was added and incubated for 20 minutes. TUNEL mixture solution (500 μL) was then added, and cells incubated in the dark for 60 minutes. Images were obtained using a phase contrast microscope (Zeiss, Oberkochen, Germany).

Lactate dehydrogenase (LDH) assay

LDH activity in cell culture medium was measured as previously described (Wang et al., 2014). Briefly, cell culture medium was collected and treated with LDH assay reaction mixture (Jiancheng, Nanjing, China) for 30 minutes at room temperature in the dark. Absorbance was measured using a microplate reader (BioTek) at 490 nm. According to the manufacturer's instructions, the cell death ratio (%) was calculated by: (Absorbancesample – Absorbanceblank) / (Absorbancemax – Absorbanceblank) × 100%, with Absorbancemax referring to the absorbance value of the positive group. The cell death ratio was expressed as LDH release.

Mitochondrial membrane potential analysis

Mitochondrial membrane potential was examined using a commercial kit (ab113852; Abcam, Cambridge, MA, USA), with tetramethylrhodamine, ethyl ester used as a specific dye for mitochondria. The experiments were performed in strict accordance with the manufacturer's instructions. Briefly, culture medium was removed and the cells incubated in working solution for 20 minutes. After incubation, working solution was evaporated and phosphate-buffered saline added. Fluorescence density was analyzed by microplate spectrophotometry (BioTek). Images were captured using a fluorescence microscope (Zeiss).

Western blot assay

Cell protein extraction was performed as previously described (Liu et al., 2016). Briefly, cells were homogenized in ice-cold tissue lysis buffer and the lysates centrifuged at 12,000 r/min for 15 minutes at 4°C. Supernatants reflected total cell protein extraction, in which protein concentration was measured using a commercial kit (Bio-Rad). Samples were boiled at 100°C for 5 minutes in Laemmli buffer. Prepared samples were subjected to western blot assay, as previously described (Sun et al., 2014). The primary antibodies used were: anti-B-cell lymphoma 2 (Bcl2), anti-Bcl2 associated X protein (Bax), and anti-β-actin. They were all rabbit polyclonal antibodies obtained from Cell Signaling Technology (Beverley, MA, USA). Membranes were incubated with primary antibodies (1:1000) at 4°C overnight. After washing, membranes were incubated with secondary antibody (1:10,000; Abcam) at room temperature for 1 hour.

Statistical analysis

Data are presented as the mean ± SEM, and were analyzed using SPSS 19.0 software (IBM, Armonk, NY, USA). Statistical significance was calculated by one-way analysis of variance followed by Bonferroni post hoc test. A value of P < 0.05 was considered statistically significant.

Results

ABPPk improved cell viability in injured dopaminergic neurons

To evaluate the potential protective role of ABPPk in dopaminergic neurons, SH-SY5Y cells were pretreated with ABPPk at different concentrations and then exposed to rotenone or 6-OHDA. We found that application of 6-OHDA or rotenone significantly reduced cell viability, while ABPPk-treated cells were resistant to exogenous insult (P < 0.01, P < 0.001; Figure 1A, B). Meanwhile, we also used primary rat dopaminergic neurons to further examine the protective role of ABPPk. Similarly, exposure of 6-OHDA or rotenone dramatically reduced cell viability, whereas application of ABPPk rescued these reductions in cell viability (P < 0.001; Figure 1C, D). Interestingly, the observed protective role of ABPPk against neurotoxic insult was dose-dependent.

Figure 1.

Figure 1

Open in a new tab

ABPPk improved cell viability detected by MTT assay in the presence of 6-OHDA and rotenone.

(A, B) SH-SY5Y cells were pretreated with different concentrations of ABPPk for 12 hours, followed by 150 μM 6-OHDA (A) or 200 μM rotenone (B) for an additional 36 hours. (C, D) Primary rat DNs were pretreated with 50 ng/mL of ABPPk and then 50 μM 6-OHDA (C) or 50 μM rotenone (D). Data are presented as the mean ± SEM (one-way analysis of variance followed by Bonferroni post hoc test). ***P < 0.001, vs. vehicle-treated cells; ##P < 0.01, ###P < 0.001, vs. cells treated with 6-OHDA or rotenone alone. ABPPk: Achyranthes bidentata polypeptide k; 6-OHDA: 6-hydroxydopamine; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DNs: dopaminergic neurons.

ABPPk attenuated LDH activity in insulted dopaminergic neurons

To further confirm the protective role of ABPPk, LDH activity was examined. We found that LDH activity in the culture medium of SH-SY5Y cells was significantly increased by 6-OHDA or rotenone (P < 0.001; Figure 2A, B). As expected, this increase was largely counteracted by ABPPk (P < 0.001; Figure 2A, B. Next, we determined whether similar protective effects of ABPPk were recapitulated in primary dopaminergic neurons. Indeed, pretreatment with ABPPk significantly reduced released LDH activity in the presence of 6-OHDA or rotenone (P < 0.001; Figure 2C, D).

Figure 2.

Figure 2

Open in a new tab

ABPPk attenuated LDH activity measured by a microplate reader in 6-OHDA- or rotenone-treated cells.

(A, B) SH-SY5Y cells were pretreated with different concentrations of ABPPk for 12 hours, followed by 150 μM 6-OHDA (A) or 200 μM rotenone (B) for an additional 36 hours. (C, D) Primary rat DNs were pretreated with 50 ng/mL of ABPPk and then 50 μM 6-OHDA (C) or 50 μM rotenone (D). Data are presented as the mean ± SEM (one-way analysis of variance followed by Bonferroni post hoc test). ***P < 0.001, vs. vehicle-treated cells; ###P < 0.001, vs. cells treated with 6-OHDA or rotenone alone. ABPPk: Achyranthes bidentata polypeptide k; LDH: lactate dehydrogenase; 6-OHDA: 6-hydroxydopamine; DNs: dopaminergic neurons.

ABPPk attenuated cell apoptosis in insulted dopaminergic neurons

We next determined whether ABPPk protects cells from apoptosis using the TUNEL assay. Briefly, TUNEL staining recognizes damaged DNA including double- and single-stranded DNA breaks (Gavrieli et al., 1992). In SH-SY5Y cells, exposure to 6-OHDA significantly induced cell apoptosis, as shown by an increase in TUNEL-positive cells (P < 0.001; Figure 3A). However, ABPPk largely attenuated cell apoptosis induced by 6-OHDA (P < 0.001; Figure 3A). Similar results were also observed in SH-SY5Y cells treated with ABPPk or rotenone alone (P < 0.001; Figure 3B).

Figure 3.

Figure 3

Open in a new tab

TUNEL assays showing cell apoptosis in SH-SY5Y cells and primary dopaminergic neurons following ABPPk treatment.

(A, B) SH-SY5Y cells were pretreated with 50 ng/mL of ABPPk for 12 hours, followed by 150 μM 6-OHDA (A) or 200 μM rotenone (B) for an additional 36 hours. (C, D) Primary DNs were pretreated with 50 ng/mL of ABPPk for 12 hours, followed by 50 μM 6-OHDA (C) or 50 μM rotenone (D) for an additional 36 hours. Cell viability was measured using the TUNEL assay. TUNEL-positive cells (red) indicate apoptotic cells. Hoechst 33342 (Thermo Fisher Scientific, Waltham, MA, USA) was used to stain the nucleus (blue). Scale bars: 50 μm. Data are presented as the mean ± SEM (one-way analysis of variance followed by Bonferroni post hoc test). ***P < 0.001, vs. vehicle-treated cells; ###P < 0.001, vs. cells treated with 6-OHDA or rotenone alone. TUNEL: Terminal deoxynucleotidyltransferase-mediated-uridine triphosphate nick-end labeling; ABPPk: Achyranthes bidentata polypeptide k; 6-OHDA: 6-hydroxydopamine; DNs: dopaminergic neurons.

In primary dopaminergic neurons, incubation of 6-OHDA or rotenone also induced cell apoptosis, while ABPPk application significantly protected these cells from apoptosis (P < 0.001; Figure 3C, D).

ABPPk improved mitochondrial function (mitochondrial membrane potential) in insulted dopaminergic neurons

Mitochondrial dysfunction has been proposed to play a major role in PD pathogenesis, and can be induced by both exogenous and endogenous neurotoxins (Schapira and Gegg, 2011). Numerous evidence has shown that rotenone and 6-OHDA are two potent inducers of mitochondrial dysfunction (Glinka and Youdim, 1995; Glinka et al., 1996; Sherer et al., 2003; Panov et al., 2005). Therefore, we determined whether ABPPk improves mitochondrial dysfunction induced by 6-OHDA or rotenone. In SH-SY5Y cells, exposure to 6-OHDA or rotenone greatly impaired mitochondrial capacity. While application of ABPPk attenuated this impairment (P < 0.001; Figure 4A, B). Moreover, in primary dopaminergic neurons, impaired mitochondrial capacity induced by 6-OHDA or rotenone was also attenuated by ABPPk (P < 0.05, P < 0.001; Figure 4C, D).

Figure 4.

Figure 4

Open in a new tab

ABPPk improved mitochondrial membrane potential in SH-SH5Y cells and primary dopaminergic neurons.

(A, B) SH-SY5Y cells were pretreated with 50 ng/mL of ABPPk for 12 hours, followed by 150 μM 6-OHDA (A) or 200 μM rotenone (B) for an additional 36 hours. (C, D) Primary dopaminergic neurons were pretreated with 50 ng/mL of ABPPk for 12 hours, followed by 50 μM 6-OHDA (C) or 50 μM rotenone (D) for an additional 36 hours. Mitochondrial staining was performed using a mitochondrial-specific Cytopainter (ab112145; Abcam, Cambridge, MA, USA), and quantified using National Institutes of Health (NIH) ImageJ software (Bethesda, MD, USA). Scale bars: 50 μm. Data are presented as the mean ± SEM (one-way analysis of variance followed by Bonferroni post hoc test). **P < 0.01, ***P < 0.001, vs. vehicle-treated cells; #P < 0.05, ###P < 0.001, vs. cells treated with 6-OHDA or rotenone alone. ABPPk: Achyranthes bidentata polypeptide k; 6-OHDA: 6-hydroxydopamine.

ABPPk increased Bcl-2/Bax in SH-SY5Y cells and primary dopaminergic neurons

Bcl-2 is a major anti-apoptotic protein and Bax is a pro-apoptotic factor. The Bcl-2/Bax ratio has been shown to determine cell fate (Mignard et al., 2014). Thus, we measured Bcl-2 and Bax protein levels by western blot assay. In SH-SY5Y cells, ABPPk alone showed no effect on Bcl-2 and Bax protein levels (P < 0.01; Figure 5A, B). Further, when cells were exposed to 6-OHDA or rotenone, Bcl-2 was reduced while Bax was enhanced. Consequently, Bcl-2/Bax ratio was dramatically reduced (Figure 5A, B). However, pretreatment of ABPPk reversed these changes in Bcl-2/Bax ratio. Similarly, in primary dopaminergic neurons, ABPPk pretreatment counteracted the effects of 6-OHDA and rotenone on Bcl-2/Bax ratio (P < 0.05, P < 0.01; Figure 5C, D).

Figure 5.

Figure 5

Open in a new tab

ABPPk increases Bcl-2/Bax ratio detected by western blot assay in injured cells.

(A, B) SH-SY5Y cells were pretreated with 50 ng/mL of ABPPk for 12 hours, followed by 150 μM 6-OHDA (A) or 200 μM rotenone (B) for an additional 36 hours to induce cell apoptosis. Protein levels of Bcl-2 and Bax were measured by western blot assay with the antibodies as indicated. (C, D) Primary rat dopaminergic neurons were pretreated with 50 ng/mL of ABPPk, followed by 50 μM 6-OHDA (C) or 50 μM rotenone (D). Protein levels of Bcl-2 and Bax were measured by western blot assay with the antibodies as indicated. Actin was used as a loading control. Data are presented as the mean ± SEM (one-way analysis of variance followed by Bonferroni post hoc test). **P < 0.01, vs. vehicle-treated cells; ††P < 0.01, vs. cells treated with ABPPk alone; #P < 0.05, ##P < 0.01, vs. cells treated with 6-OHDA or rotenone alone. ABPPk: Achyranthes bidentata polypeptide k; 6-OHDA: 6-hydroxydopamine; DNs: dopaminergic neurons.

Discussion

In this study, SH-SH5Y cells and primary dopaminergic neurons were pretreated with ABPPk, the most active fraction isolated from the traditional Chinese medicine, Achyranthes bidentata. Our results show that ABPPk markedly protects cells from apoptosis induced by 6-OHDA or rotenone. Moreover, our findings show that ABPPk stimulates the Bcl-2/Bax ratio in insulted dopaminergic neurons. Altogether, these data indicate that ABPPk has a potent neuroprotective role in dopaminergic neurons and might be used as an intervention against PD.

PD is the second most common neurodegeneration disorder, affecting over four million people, and with pronounced loss of dopaminergic neurons in the substantia nigra. Over 90% of PD cases do not have an identified genetic cause, and environmental factors likely contribute to the disease. 6-OHDA and rotenone are two types of chemicals with selective destroying roles on dopaminergic neurons. Thus, these two chemicals are widely used for generating PD models both in vitro and in vivo (Qiu et al., 2016). Here, we used 6-OHDA and rotenone to treat SH-SY5Y and primary dopaminergic neurons and create an in vitro model of PD. Indeed, exposure to these two neurotoxins greatly reduced cell viability. Of note, low dosage of 6-OHDA and rotenone was used for the primary dopaminergic neurons, suggesting that primary dopaminergic neurons are vulnerable to these exogenous neurotoxins. This conclusion is in agreement with a previous study (Aime et al., 2015).

Extensive studies of Achyranthes bidentata suggest that it has multiple physiological functions including adipogenesis inhibition, anti-oxidative stress, promotion of osteogenic differentiation, and chondrocyte proliferation (Tie et al., 2013; Oh et al., 2014; Suh et al., 2014). Saponins and polysaccharides are considered the two main constituents of Achyranthes bidentata that are responsible for its pharmaceutical efficacy. Recently, we prepared a polypeptide extraction from Achyranthes bidentata blume (i.e., ABPP) and found that ABPP exhibits neurotrophic and neuroprotective actions in several types of neurons (Shen et al., 2008; Shen et al., 2013). To obtain the most potent fraction of ABPP, we separated crude ABPP by high performance liquid chromatography, with one fraction (namely ABPPk) showing the greatest neuroprotective action both in vitro and in vivo (Cheng et al., 2014; Yu et al., 2014). In the present study, we focused on ABPPk and its potential application for treating diseases associated with neuronal loss.

Since dopaminergic neuronal loss is a main causative factor for developing PD, we hypothesized that ABPPk might play a beneficial role against PD by preventing neuronal apoptosis. To test this hypothesis, SH-SY5Y cells were treated with ABPPk, followed by 6-OHDA or rotenone. As expected, ABPPk treatment significantly rescued cells from apoptosis. Similarly, 6-OHDA or rotenone-induced cytotoxicity was greatly attenuated by ABPPk in primary dopaminergic neurons. These findings are consistent with previous studies showing potent neuroprotective efficacy of ABPP in several different types of neurons injured by various toxic agents or myocardial ischemia (Shen et al., 2008, 2010, 2011, 2013; Yu et al., 2014). Moreover, we previously demonstrated that ABPPk can enhance neuronal growth in vitro and promote peripheral nerve regeneration after crush injury in vivo (Cheng et al., 2014). It should be noted that these findings, together with our current data, are all obtained from cell models. Therefore, to further ascertain the potential application of ABPPk for treating diseases associated with neuronal loss, such as PD, in vivo PD animal models should be used.

In summary, purified ABPPk fraction exhibits potent neuroprotective effects on dopaminergic neurons, suggesting that ABPPk might be a potential drug for treating neuronal loss associated with diseases such as PD. Consequently, we have an ongoing project investigating the effect of ABPPk using an in vivo PD model. The structure of ABPPk is still unknown. Thus, future research will be focused on the structure of ABPPk, which will shed light on the molecular mechanisms underlying its neuroprotective role. Moreover, recombinant ABPPk will be produced by genetic engineering to pave the way for its clinical application.

Footnotes

Conflicts of interest: The authors declare that they have no competing financial interests.

Financial support: This study was supported by the National Natural Science Foundation of China, No. 81471037, 81770841; a grant from the Basic Research of Jiangsu Education Department of China, No. 14KJA180006; a grant from the Six Talent Summit Project of Jiangsu Province of China, No. SWYY-051; a grant from the Priority Academic Program Development of Jiangsu Higher Education Institutions of China. The funders had no involvement in the study design; data collection, analysis, and interpretation; paper writing; or decision to submit the paper for publication.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open peer reviewers: Kun-Che Chang, Stanford University, USA; Puneet Bagga, University of Pennsylvania Perelman School of Medicine, USA.

Funding: This study was supported by the National Natural Science Foundation of China, No. 81471037, 81770841; a grant from the Basic Research of Jiangsu Education Department of China, No. 14KJA180006; a grant from the Six Talent Summit Project of Jiangsu Province of China, No. SWYY-051; a grant from the Priority Academic Program Development of Jiangsu Higher Education Institutions of China.

(Copyedited by James R, Stow A, Yu J, Li CH, Qiu Y, Song LP, Zhao M)

References

  • 1.Aime P, Sun X, Zareen N, Rao A, Berman Z, Volpicelli-Daley L, Bernd P, Crary JF, Levy OA, Greene LA. Trib3 is elevated in Parkinson's disease and mediates death in Parkinson's disease models. J Neurosci. 2015;35:10731–10749. doi: 10.1523/JNEUROSCI.0614-15.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cheng Q, Jiang C, Wang C, Yu S, Zhang Q, Gu X, Ding F. The Achyranthes bidentata polypeptide k fraction enhances neuronal growth in vitro and promotes peripheral nerve regeneration after crush injury in vivo. Neural Regen Res. 2014;9:2142–2150. doi: 10.4103/1673-5374.147948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov AY. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell. 2009;33:627–638. doi: 10.1016/j.molcel.2009.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Glinka Y, Tipton KF, Youdim MB. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem. 1996;66:2004–2010. doi: 10.1046/j.1471-4159.1996.66052004.x. [DOI] [PubMed] [Google Scholar]
  • 6.Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol. 1995;292:329–332. doi: 10.1016/0926-6917(95)90040-3. [DOI] [PubMed] [Google Scholar]
  • 7.He G, Guo W, Lou Z, Zhang H. Achyranthes bidentata saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK MAPK signaling pathway. Cell Biochem Biophys. 2014;70:467–473. doi: 10.1007/s12013-014-9942-3. [DOI] [PubMed] [Google Scholar]
  • 8.Jiang Z, Qian J, Dong H, Yang J, Yu X, Chen J, Chen H, Shi Q, Jia L. The traditional Chinese medicine achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017;7:3888. doi: 10.1038/s41598-017-02054-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kong LY, Tan RX. Artemisinin, a miracle of traditional Chinese medicine. Nat Prod Rep. 2015;32:1617–1621. doi: 10.1039/c5np00133a. [DOI] [PubMed] [Google Scholar]
  • 10.Liu X, Zhao Y, Peng S, Zhang S, Wang M, Chen Y, Zhang S, Yang Y, Sun C. BMP7 retards peripheral myelination by activating p38 MAPK in Schwann cells. Sci Rep. 2016;6:31049. doi: 10.1038/srep31049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Mignard V, Lalier L, Paris F, Vallette FM. Bioactive lipids and the control of Bax pro-apoptotic activity. Cell Death Dis. 2014;5:e1266. doi: 10.1038/cddis.2014.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Oh SD, Kim M, Min BI, Choi GS, Kim SK, Bae H, Kang C, Kim DG, Park BJ, Kim CK. Effect of Achyranthes bidentata Blume on 3T3-L1 adipogenesis and rats fed with a high-fat diet. Evid Based Complement Alternat Med. 2014;2014:158018. doi: 10.1155/2014/158018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem. 2005;280:42026–42035. doi: 10.1074/jbc.M508628200. [DOI] [PubMed] [Google Scholar]
  • 14.Qiu S, Li JG, Qiu Q, Chen H, Xiang ZM. Caffeic acid phenethyl ester against cellular injuries in the rotenone-induced Parkinson's disease model. Zhongguo Zuzhi Gongcheng Yanjiu. 2016;20:5979–5985. [Google Scholar]
  • 15.Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis. 2011;2011:159160. doi: 10.4061/2011/159160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shen H, Wu X, Zhu Y, Sun H. Intravenous administration of achyranthes bidentata polypeptides supports recovery from experimental ischemic stroke in vivo. PLoS One. 2013;8:e57055. doi: 10.1371/journal.pone.0057055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shen H, Yuan Y, Ding F, Liu J, Gu X. The protective effects of Achyranthes bidentata polypeptides against NMDA-induced cell apoptosis in cultured hippocampal neurons through differential modulation of NR2A- and NR2B-containing NMDA receptors. Brain Res Bull. 2008;77:274–281. doi: 10.1016/j.brainresbull.2008.08.002. [DOI] [PubMed] [Google Scholar]
  • 18.Shen H, Yuan Y, Ding F, Hu N, Liu J, Gu X. Achyranthes bidentata polypeptides confer neuroprotection through inhibition of reactive oxygen species production, Bax expression, and mitochondrial dysfunction induced by overstimulation of N-methyl-D-aspartate receptors. J Neurosci Res. 2010;88:669–676. doi: 10.1002/jnr.22221. [DOI] [PubMed] [Google Scholar]
  • 19.Shen Y, Zhang Q, Gao X, Ding F. An active fraction of Achyranthes bidentata polypeptides prevents apoptosis induced by serum deprivation in SH-SY5Y cells through activation of PI3K/Akt/Gsk3beta pathways. Neurochem Res. 2011;36:2186–2194. doi: 10.1007/s11064-011-0543-x. [DOI] [PubMed] [Google Scholar]
  • 20.Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003;23:10756–10764. doi: 10.1523/JNEUROSCI.23-34-10756.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Suh KS, Lee YS, Choi EM. The protective effects of Achyranthes bidentata root extract on the antimycin A induced damage of osteoblastic MC3T3-E1 cells. Cytotechnology. 2014;66:925–935. doi: 10.1007/s10616-013-9645-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Sun C, Wang M, Liu X, Luo L, Li K, Zhang S, Wang Y, Yang Y, Ding F, Gu X. PCAF improves glucose homeostasis by suppressing the gluconeogenic activity of PGC-1alpha. Cell Rep. 2014;9:2250–2262. doi: 10.1016/j.celrep.2014.11.029. [DOI] [PubMed] [Google Scholar]
  • 23.Tie R, Ji L, Nan Y, Wang W, Liang X, Tian F, Xing W, Zhu M, Li R, Zhang H. Achyranthes bidentata polypeptides reduces oxidative stress and exerts protective effects against myocardial ischemic/reperfusion injury in rats. Int J Mol Sci. 2013;14:19792–19804. doi: 10.3390/ijms141019792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang CP, Li GC, Shi YW, Zhang XC, Li JL, Wang ZW, Ding F, Liang XM. Neuroprotective effect of schizandrin A on oxygen and glucose deprivation/reperfusion-induced cell injury in primary culture of rat cortical neurons. J Physiol Biochem. 2014;70:735–747. doi: 10.1007/s13105-014-0342-3. [DOI] [PubMed] [Google Scholar]
  • 25.Wang Y, Shen W, Yang L, Zhao H, Gu W, Yuan Y. The protective effects of Achyranthes bidentata polypeptides on rat sciatic nerve crush injury causes modulation of neurotrophic factors. Neurochem Res. 2013;38:538–546. doi: 10.1007/s11064-012-0946-3. [DOI] [PubMed] [Google Scholar]
  • 26.Yu S, Wang C, Cheng Q, Xu H, Zhang S, Li L, Zhang Q, Gu X, Ding F. An active component of Achyranthes bidentata polypeptides provides neuroprotection through inhibition of mitochondrial-dependent apoptotic pathway in cultured neurons and in animal models of cerebral ischemia. PLoS One. 2014;9:e109923. doi: 10.1371/journal.pone.0109923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yuan Y, Shen H, Yao J, Hu N, Ding F, Gu X. The protective effects of Achyranthes bidentata polypeptides in an experimental model of mouse sciatic nerve crush injury. Brain Res Bull. 2010;81:25–32. doi: 10.1016/j.brainresbull.2009.07.013. [DOI] [PubMed] [Google Scholar]
  • 28.Zou Y, Meng J, Chen W, Liu J, Li X, Li W, Lu C, Shan F. Modulation of phenotypic and functional maturation of murine dendritic cells (DCs) by purified Achyranthes bidentata polysaccharide (ABP) Int Immunopharmacol. 2011;11:1103–1108. doi: 10.1016/j.intimp.2011.03.006. [DOI] [PubMed] [Google Scholar]

Articles from Neural Regeneration Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES